Literature DB >> 26438594

Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.

Andrea Ponzetta1, Giorgia Benigni1, Fabrizio Antonangeli1, Giuseppe Sciumè1, Emilio Sanseviero1, Alessandra Zingoni1, Maria Rosaria Ricciardi2, Maria Teresa Petrucci2, Angela Santoni3, Giovanni Bernardini3.   

Abstract

Natural killer (NK) cells are key innate immune effectors against multiple myeloma, their activity declining in multiple myeloma patients with disease progression. To identify the mechanisms underlying NK cell functional impairment, we characterized the distribution of functionally distinct NK cell subsets in the bone marrow of multiple myeloma-bearing mice. Herein we report that the number of KLRG1(-) NK cells endowed with potent effector function rapidly and selectively decreases in bone marrow during multiple myeloma growth, this correlating with decreased bone marrow NK cell degranulation in vivo. Altered NK cell subset distribution was dependent on skewed chemokine/chemokine receptor axes in the multiple myeloma microenvironment, with rapid downmodulation of the chemokine receptor CXCR3 on NK cells, increased CXCL9 and CXCL10, and decreased CXCL12 expression in bone marrow. Similar alterations in chemokine receptor/chemokine axes were observed in patients with multiple myeloma. Adoptive transfer experiments demonstrated that KLRG1(-) NK cell migration to the bone marrow was more efficient in healthy than multiple myeloma-bearing mice. Furthermore, bone marrow localization of transferred CXCR3-deficient NK cells with respect to wild type was enhanced in healthy and multiple myeloma-bearing mice, suggesting that CXCR3 restrains bone marrow NK cell trafficking. Our results indicate that multiple myeloma-promoted CXCR3 ligand upregulation together with CXCL12 downmodulation act as exit signals driving effector NK cells outside the bone marrow, thus weakening the antitumor immune response at the primary site of tumor growth. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26438594     DOI: 10.1158/0008-5472.CAN-15-1320

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

2.  Expression of CD94 by ex vivo-differentiated NK cells correlates with the in vitro and in vivo acquisition of cytotoxic features.

Authors:  Meriem Hasmim; Nadine Khalife; Yanyan Zhang; Manale Doldur; Geralidne Visentin; Stéphane Terry; Julien Giron-Michel; Ruoping Tang; François Delhommeau; Nicolas Dulphy; Jean-Henri Bourhis; Fawzia Louache; Salem Chouaib
Journal:  Oncoimmunology       Date:  2017-07-18       Impact factor: 8.110

3.  Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells.

Authors:  Fabrizio Antonangeli; Alessandra Soriani; Biancamaria Ricci; Andrea Ponzetta; Giorgia Benigni; Stefania Morrone; Giovanni Bernardini; Angela Santoni
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

4.  The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide.

Authors:  Subhashis Sarkar; Sachin K S Chauhan; John Daly; Alessandro Natoni; Heather Fairfield; Robert Henderson; Emma Nolan; Dawn Swan; Jinsong Hu; Michaela R Reagan; Michael O'Dwyer
Journal:  Cancer Immunol Immunother       Date:  2020-01-09       Impact factor: 6.968

5.  CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model.

Authors:  Yu Yang Ng; Zhicheng Du; Xi Zhang; Wee Joo Chng; Shu Wang
Journal:  Cancer Gene Ther       Date:  2021-09-01       Impact factor: 5.987

Review 6.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

7.  Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.

Authors:  Oksana Zavidij; Nicholas J Haradhvala; Tarek H Mouhieddine; Romanos Sklavenitis-Pistofidis; Songjie Cai; Mairead Reidy; Mahshid Rahmat; Abdallah Flaifel; Benjamin Ferland; Nang K Su; Michael P Agius; Jihye Park; Salomon Manier; Mark Bustoros; Daisy Huynh; Marzia Capelletti; Brianna Berrios; Chia-Jen Liu; Meng Xiao He; Esteban Braggio; Rafael Fonseca; Yosef E Maruvka; Jennifer L Guerriero; Melissa Goldman; Eliezer M Van Allen; Steven A McCarroll; Jamil Azzi; Gad Getz; Irene M Ghobrial
Journal:  Nat Cancer       Date:  2020-04-27

Review 8.  The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.

Authors:  Sarah A Holstein; Nizar Bahlis; P Leif Bergsagel; Manisha Bhutani; Niccolo Bolli; Carrie Brownstein; Pierre Demolis; David Foureau; Francesca Gay; Irene M Ghobrial; Nicole Gormley; Jens Hillengass; Martin Kaiser; Marcela V Maus; J Joseph Melenhorst; Maximilian Merz; Michael O Dwyer; Bruno Paiva; Marcelo C Pasquini; Nina Shah; Sandy W Wong; Saad Z Usmani; Philip L McCarthy
Journal:  Transplant Cell Ther       Date:  2021-06-06

Review 9.  Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases.

Authors:  Giovanni Bernardini; Fabrizio Antonangeli; Valentina Bonanni; Angela Santoni
Journal:  Front Immunol       Date:  2016-10-06       Impact factor: 7.561

Review 10.  The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.

Authors:  Tobias Bald; Matthew F Krummel; Mark J Smyth; Kevin C Barry
Journal:  Nat Immunol       Date:  2020-07-20       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.